-
International Journal of Nephrology and Renovascular Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Complete response of a metastatic gastroesophageal adenocarcinoma on irinotecan-based chemotherapy in a dialysis patient
Case report
(1338) Views (539) Full article downloads
Authors: J Verwimp, F Geurs, S Ponette, et al
Published Date May 2010
Volume 2010:3 Pages 61 - 64
DOI: http://dx.doi.org/10.2147/IJNRD.S7650
J Verwimp1, F Geurs1, S Ponette2, J Ponette2, J Martens3, K Bulté2
1Department of Medical Oncology, 2Department of Gastroenterology, 3Department of Nephrology, Regionaal Ziekenhuis Sint-Maria, Ziekenhuislaan, Halle, Belgium
Abstract: We present the first case report of a complete response of metastatic gastroesophageal cancer in a chronic hemodialysis patient with irinotecan-based chemotherapy. An elderly dialysis patient presented with diffuse liver metastases by a gastroesophageal adenocarcinoma. He received combination chemotherapy with 5 fluorouracil and irinotecan. After six months of chemotherapy, liver scans show complete remission. The principles, practice, and experience of chemotherapy with irinotecan during dialysis are discussed.
Keywords: gastroesophageal cancer, irinotecan, chemotherapy, dialysis
Other articles by Dr Filip Geurs
Urachal carcinoma with liver, lung, and brain metastases: benefit of a new combination chemotherapy (bevacizumab, 5-fluorouracil, irinotecan) – case reportWeekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
- Potential renovascular hypertension, space missions, and the role of magnesium
- The use of everolimus in renal-transplant patients
- Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
